Holly May has served as President of BioLineRx USA since September 2022. From June 2022 to September 2022, Ms. May served as Chief Commercial Officer. Prior to joining BioLineRx, she was CCO at AVROBIO, where she was responsible for building the company’s global commercial organization inclusive of driving the development and execution of commercial strategy. Prior to that, she served as VP & Head of Commercial at SOBI, Inc., where she led all aspects of commercial strategy, operations, and performance. Before SOBI, Ms. May held leadership roles of increasing strategic importance across marketing, operations, sales, and planning at Sanofi and Genzyme, with her last roles encompassing VP in the Genzyme rare disease unit, and head of marketing operations/strategic planning for Sanofi’s global oncology division. She holds a BA in Zoology from Miami University of Ohio, and an MBA with a concentration in marketing from the University of Akron.